Sign in
PFE-PFIZER INC

Pfizer Maintains Strong Dividend and Growth Potential Amid Stock Challenges and Declining COVID Sales

Tuesday

03 December, 2024

As Pfizer navigates a transformative phase, it continues to reward shareholders with a strong dividend yield of 6.5% to 6.8%, even amidst challenges like declining COVID-19 sales. Can a robust oncology division and strategic acquisitions pave the way for long-term growth despite looming patent expirations?

article image for PFE

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
65
Key Takeaways
  • Pfizer offers an appealing dividend yield between 6.5% and 6.8%, backed by substantial free cash flow.
  • The oncology sector is performing well, with a notable 31% rise in cancer treatment sales.
  • Recent acquisitions, including Seagen for $43 billion, bolster Pfizer's growth prospects with numerous drug candidates.
  • The company's forward P/E ratio of 8.8 suggests it is well-priced relative to competitors.
  • Analysts foresee a 28% increase, highlighting significant recovery and growth potential for investors.
More on PFIZER INC
Read more insights on PFIZER INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.